Phase 1 Narcolepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your Body Mass Index (BMI) — a measure of body weight relative to height — must be between 18.0 and 30.0
- You must weigh more than 50 kilograms (about 110 pounds)
- You must be a non-smoker, or must have stopped smoking at least 3 months before your screening appointment, confirmed by a urine or blood test
Who may not be able to join:
- You have had a fever or any other sudden illness in the 14 days before your first dose of the study drug that has not completely cleared up
- You have any condition that could affect how your body absorbs medication (confirm with trial site)
- If you are female: you are able to become pregnant, are currently pregnant, are breastfeeding, or are planning to become pregnant or donate eggs during the study or within 90 days after your last dose of the study drug
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 617-341-6777
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs); Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs); Part C: Maximum Observed Plasma Concentration (Cmax) of Midazolam in the Absence and Presence of VX-433; Part C: Maximum Observed Plasma Concentration (Cmax) of Bupropion and Hydroxybupropion in the Absence and Presence of VX-433; Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in the Absence and Presence of VX...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.